Breakout Ventures Raises $114M for Third Fund

A San Francisco-based venture capital firm has secured $114 million for its third and largest fund, placing a significant bet on the profound and inseparable convergence of artificial intelligence and biology. The firm argues that the most transformative companies of the coming decade will be built by founders who possess a deep understanding of both fields. This new capital will be directed toward startups where advanced computational tools are being used to radically accelerate scientific discovery and product development, particularly in areas like drug discovery and advanced materials.

Breakout Ventures originated from an unconventional starting point. In 2011, Lindy Fishburne launched a grant program called Breakout Labs within the Thiel Foundation. Its mission was to fund scientist-entrepreneurs tackling problems deemed too radical for traditional venture capital and too commercially focused for academic grants. By 2016, it became clear that these pioneering companies needed more substantial, growth-oriented capital. This led Fishburne and her colleague Julia Moore to establish Breakout Ventures as a full-fledged venture firm, closing their first $60 million fund in 2017 and a second fund of $112.5 million in 2021.

While labeling a fund as “AI-focused” is commonplace today, Breakout’s interpretation is notably specific. The firm believes the highest-value opportunities lie not in generic AI applications but in systems that can genuinely compress the timeline from scientific insight to real-world medicine and products. Their focus is on the critical intersection where computation meets the lab bench, aiming to fund the infrastructure and tools that make this acceleration possible.

With this latest close, the firm now manages over $230 million in total assets. The partnership, still led by managing partners Fishburne and Moore, has grown to include Dana Watt, a diagnostics founder, and Nima Ronaghi, an organic chemist focused on guiding scientists through the founder transition. The operational team includes CFO James Chan, general counsel Ziv Yoash, and director of platform Susanna Harris.

The existing portfolio from Breakout’s earlier funds vividly illustrates its investment thesis. Companies like Noetik employ self-supervised machine learning on complex tumor data to discover new cancer immunotherapies. Phantom Neuro develops neural signal processing for intuitive prosthetic control. Another, ZymoChem, uses engineered enzymes to produce bio-based chemicals at costs competitive with petroleum. These companies, united by a founder profile of scientist-engineers building where the commercial moat is the science itself, demonstrate the firm’s consistent philosophy over the past fifteen years.

This long-held conviction now appears exceptionally well-timed. The idea that AI will fundamentally reshape biology has moved from a niche belief to a central industry assumption, accelerated by breakthroughs like AlphaFold. A new generation of companies is leveraging foundation models trained on biological data and tools that simply didn’t exist a decade ago, dramatically shortening development cycles across the life sciences.

Fund III will invest from the pre-seed through Series A stages, maintaining the firm’s strategy of being the first institutional investor in science-driven companies and supporting them through subsequent growth rounds. The focus sectors remain biotech and life sciences, healthcare and digital health, robotics and automation, and the critical developer tools and computational infrastructure that enable all the above.

For an initiative that began by funding ideas considered too speculative for investment, a $114 million fund represents a powerful validation. The radical science Breakout supported in its earliest days now appears not just plausible, but inevitable, charting the course for the next wave of technological integration in biology.

(Source: The Next Web)